Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis

November 4, 2026 updated by: Anthonius Santoso Rulie, Universitas Indonesia

The Effect of Manual Acupuncture on Intradialytic Nausea and Vomiting Scores in Patients With Chronic Kidney Disease Undergoing Routine Hemodialysis: A Randomized Controlled Trial

This study aims to evaluate the immediate effects of acupuncture therapy at three specific acupuncture points (PC6, ST36, and KI3) on intradialysis nausea and vomiting in patients with chronic kidney disease undergoing regular hemodialysis. The outcome will be assessed using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR) score one hour during the treatment and two hours after completion of hemodialysis.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • DKI Jakarta
      • Jakarta Pusat, DKI Jakarta, Indonesia, 10430

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 59 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with chronic kidney disease (CKD) who experience intradialytic nausea and vomiting, undergo routine hemodialysis twice weekly for at least 6 months, and are hemodynamically stable.
  • Subjects aged 18-59 years.
  • Subjects who have not received acupuncture therapy within at least one month prior to the study.
  • Subjects who are willing to participate in the study according to the scheduled protocol until completion and who have signed the informed consent form.

Exclusion Criteria:

  • Subjects with malignancies or infected wounds at the acupuncture point sites intended for intervention.
  • Subjects with primary skin diseases, such as allergic dermatitis, irritant contact dermatitis, neurodermatitis, and psoriasis.
  • Subjects with a history of hypersensitivity reactions to previous acupuncture therapy, including stainless steel allergy, atopy, keloid formation, or other hypersensitivity reactions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Manual Acupuncture

Manual acupuncture is performed at bilateral PC6 (Neiguan), ST36 (Zusanli), and KI3 (Taixi) using sterile Huanqiu® needles (0.25 × 25 mm) inserted 20 mm deep through a hole in a transparent waterproof Onemed® plaster, guided by a 20-mm tube. Needles are retained for 20 minutes without manipulation and then removed, twice per treatment period. Sample are blindfolded during the procedure. Device: Manual Acupuncture The manual acupuncture is using sterile Huanqiu® needles

The manual acupuncture is using sterile Huanqiu® needles

Sham Comparator: Sham Acupuncture

Manual acupuncture is performed at bilateral PC6 (Neiguan), ST36 (Zusanli), and KI3 (Taixi) using with blunt-tipped needles that only press against an intact plaster without penetrating the skin above the Onemed® plaster, pressed by a 20-mm tube, controlling for pressure sensation and expectation. Sample are blindfolded during the procedure.

Device: Sham Acupuncture The sham acupuncture using blunt-tipped needles

The sham acupuncture using blunt-tipped needles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rhodes Index of Nausea, Vomiting and Retching (RINVR)
Time Frame: baseline (after dialysis is running for 1 hour), 2 hours after dialysis is finished
baseline (after dialysis is running for 1 hour), 2 hours after dialysis is finished

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Medical Acupuncture Study Program FKUI, Medical Acupuncture Study Program Faculty of Medicine Universitas Indonesia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 15, 2026

First Submitted That Met QC Criteria

October 15, 2026

First Posted (Actual)

October 22, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 0328/EC/KEPK/09/2026_

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.